Joseph J. Eron

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Joseph J. Eron, Patrick Yéni, Joseph Gathe et al. · The Lancet · 2006 · 342 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Joseph J. Eron, Bonaventura Clotet, J. Durant et al. · The Journal of Infectious Diseases · 2012 · 312 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results

Robert L. Murphy, Scott Brun, Charles B. Hicks et al. · AIDS · 2001 · 239 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

Roy T. Steigbigel, David A. Cooper, Hedy Teppler et al. · Clinical Infectious Diseases · 2010 · 205 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

Joseph J. Eron, Jürgen K. Rockstroh, Jacques Reynes et al. · The Lancet Infectious Diseases · 2011 · 191 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +8